EYPT vs RGNX

EyePoint Inc has undergone a material positive transformation since the last analysis, with its lead candidate EYP-1901 (now branded VERISERT) for wet AMD achieving accelerated FDA approval in early 2026, following highly positive Phase 3 results in late 2025. This de-risks the primary clinical hurdle, validating EyePoint's Durasert sustained-release technology and suprachoroidal delivery platform...

Regenxbio faces a significantly elevated risk profile since the last analysis. While its proprietary NAV gene therapy platform and the lead asset RGX-314 (wet AMD) with the AbbVie partnership still offer multi-billion dollar market potential, recent events have introduced substantial uncertainty. The FDA clinical holds on two key pipeline assets (RGX-111 and RGX-121), including a neoplasm case, ra...